Similar articles for PMID: 15876399

Year	Number of Results
1953	1
1955	1
1957	1
1959	1
1962	1
1963	1
1965	2
1966	1
1967	1
1968	1
1969	2
1970	1
1971	1
1977	1
1983	1
1985	2
1988	1
1989	1
1991	1
1993	1
1994	2
1997	3
1998	4
1999	4
2000	4
2001	4
2002	8
2003	3
2004	17
2005	23
2006	16
2007	17
2008	17
2009	11
2010	9
2011	5
2012	5
2013	6
2014	4
2015	9
2016	4
2017	2
2018	7
2019	4
2020	2
2021	3
2022	6
2023	1
2024	0

1

The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics.

Yasuda Y, Kaleta J, Brömme D. Yasuda Y, et al. Adv Drug Deliv Rev. 2005 May 25;57(7):973-93. doi: 10.1016/j.addr.2004.12.013. Epub 2005 Apr 15. Adv Drug Deliv Rev. 2005. PMID: 15876399 Review.

2

Cathepsin K inhibitor-polymer conjugates: potential drugs for the treatment of osteoporosis and rheumatoid arthritis.

Wang D, Li W, Pechar M, Kopecková P, Brömme D, Kopecek J. Wang D, et al. Int J Pharm. 2004 Jun 11;277(1-2):73-9. doi: 10.1016/j.ijpharm.2003.03.003. Int J Pharm. 2004. PMID: 15158970 Review.

3

Drug delivery strategies for cathepsin inhibitors in joint diseases.

Wang D, Brömme D. Wang D, et al. Expert Opin Drug Deliv. 2005 Nov;2(6):1015-28. doi: 10.1517/17425247.2.6.1015. Expert Opin Drug Deliv. 2005. PMID: 16296806 Review.

4

6. Cathepsin K inhibitors: their potential as anti-osteoporosis agents.

Deaton DN, Kumar S. Deaton DN, et al. Prog Med Chem. 2004;42:245-375. doi: 10.1016/S0079-6468(04)42006-2. Prog Med Chem. 2004. PMID: 15003723 Review. No abstract available.

5

Cathepsin K inhibitors: a novel target for osteoporosis therapy.

Stoch SA, Wagner JA. Stoch SA, et al. Clin Pharmacol Ther. 2008 Jan;83(1):172-6. doi: 10.1038/sj.clpt.6100450. Epub 2007 Dec 12. Clin Pharmacol Ther. 2008. PMID: 18073778 Review.

6

Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k.

Tavares FX, Boncek V, Deaton DN, Hassell AM, Long ST, Miller AB, Payne AA, Miller LR, Shewchuk LM, Wells-Knecht K, Willard DH Jr, Wright LL, Zhou HQ. Tavares FX, et al. J Med Chem. 2004 Jan 29;47(3):588-99. doi: 10.1021/jm030373l. J Med Chem. 2004. PMID: 14736240

7

5-Aminopyrimidin-2-ylnitriles as cathepsin K inhibitors.

Morley AD, Kenny PW, Burton B, Heald RA, Macfaul PA, Mullett J, Page K, Porres SS, Ribeiro LR, Smith P, Ward S, Wilkinson TJ. Morley AD, et al. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1658-61. doi: 10.1016/j.bmcl.2009.01.110. Epub 2009 Feb 6. Bioorg Med Chem Lett. 2009. PMID: 19231183

8

An orally active cathepsin K inhibitor, furan-2-carboxylic acid, 1-{1-[4-fluoro-2-(2-oxo-pyrrolidin-1-yl)-phenyl]-3-oxo-piperidin-4-ylcarbamoyl}-cyclohexyl)-amide (OST-4077), inhibits osteoclast activity in vitro and bone loss in ovariectomized rats.

Kim MK, Kim HD, Park JH, Lim JI, Yang JS, Kwak WY, Sung SY, Kim HJ, Kim SH, Lee CH, Shim JY, Bae MH, Shin YA, Huh Y, Han TD, Chong W, Choi H, Ahn BN, Yang SO, Son MH. Kim MK, et al. J Pharmacol Exp Ther. 2006 Aug;318(2):555-62. doi: 10.1124/jpet.106.102798. Epub 2006 May 12. J Pharmacol Exp Ther. 2006. PMID: 16699068

9

Cathepsin K, osteoclastic resorption, and osteoporosis therapy.

Zaidi M, Troen B, Moonga BS, Abe E. Zaidi M, et al. J Bone Miner Res. 2001 Oct;16(10):1747-9. doi: 10.1359/jbmr.2001.16.10.1747. J Bone Miner Res. 2001. PMID: 11585336 Free article. Review. No abstract available.

10

Biochemical properties and regulation of cathepsin K activity.

Lecaille F, Brömme D, Lalmanach G. Lecaille F, et al. Biochimie. 2008 Feb;90(2):208-26. doi: 10.1016/j.biochi.2007.08.011. Epub 2007 Sep 2. Biochimie. 2008. PMID: 17935853 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

209 results

Results by year